Desmopressin Incidents Indicate Need for Pharmacist Involvement in Development and Use of Monitoring Protocols

Authors

  • Julie Greenall Institute for Safe Medication Practices Canada
  • Mary Jane Campigotto Institute for Safe Medication Practices Canada
  • Sylvia Hyland Institute for Safe Medication Practices Canada
  • Christine Koczmara Institute for Safe Medication Practices Canada

DOI:

https://doi.org/10.4212/cjhp.v61i3.58

Abstract

Arecent ISMP Canada Safety Bulletin1 described safety concerns related to fluid management and desmopressin therapy. Here, we review selected information and excerpts from that bulletin that are highly relevant to hospital pharmacists. One of the key recommendations in the bulletin was to develop a protocol for monitoring patients who require desmopressin therapy. Development of standardized protocols and predefined order sets to assist in the management of selected patient groups is a highleverage strategy for enhancing consistency and incorporating best practices into patient care processes.

Downloads

Download data is not yet available.

Downloads

Published

2009-04-09

Issue

Section

Safe Medication Practices / Pratiques d'utilisation sécuritaire des médicaments